BioMotiv

CEO Baiju R. Shah leads investment strategy and firm operations, with Managing Director Michael D. Sosin overseeing deal execution. Both have extensive backgrounds in life sciences entrepreneurship and venture capital (per public record).

BioMotiv's primary deal flow comes through the Harrington Discovery Institute, an affiliated nonprofit that identifies and funds early-stage academic research with therapeutic potential. This exclusive pipeline gives BioMotiv access to discoveries from leading academic medical centers before they reach the broader venture market.

BioMotiv operates as a mission-driven asset manager rather than a family office. It was founded with philanthropic backing from the Harrington Project and functions as a for-profit investment entity that raises capital from institutional investors, similar to a specialized venture firm.

BioMotiv focuses exclusively on direct investments — specifically, it builds new portfolio companies from the ground up rather than making minority equity investments in existing firms. Each portfolio company is typically created as a standalone entity.

The firm targets preclinical through Phase I-stage therapeutic programs, as well as early-stage medical device and diagnostic opportunities. It typically funds and operates companies through initial proof-of-concept and Phase I clinical data before seeking external partners or later-stage investors.

BioMotiv does not publicly state explicit exclusion criteria, but its disclosed portfolio suggests a focus on human therapeutics, medical devices, and diagnostics, with no disclosed activity in digital health, health IT, or later-stage biotech.

BioMotiv was launched through the Harrington Project, a nonprofit initiative based at University Hospitals in Cleveland funded by philanthropist Dr. Michael J. Harrington. The firm itself is not a family office but a for-profit entity supported by institutional capital.